Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with acute pouchitis
It is very uncertain whether metronidazole changes adverse events compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical remission · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical remission compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical improvement · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical improvement compared with budesonide enema (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
It is very uncertain whether effects of different inhaled corticosteroids on growth in children… changes linear growth velocity (cm/year) compared with budesonide (very low certainty).
1 finding from 1 review
Change in height · children up to 18 years of age with persistent asthma
Effects of different inhaled corticosteroids on growth in children… probably leads to higher change in height (cm) over a period of time compared with budesonide (moderate certainty).
1 finding from 1 review
Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine may leads to higher maintenance of remission compared with budesonide (low certainty).
1 finding from 1 review
Nasal obstruction during the 4th week of treatment Number of responders · patients with non‐allergic rhinitis
Capsaicin showed no clear difference in nasal obstruction during the 4th week of treatment Number of… compared with budesonide (low certainty).
1 finding from 1 review
Aggregate relief score during the 4th week of treatment · patients with non‐allergic rhinitis
1 finding from 1 review
Treatment‐related adverse events · patients with non‐allergic rhinitis
The review found no eligible studies for this question.
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review
Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with budesonide (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
1 finding from 1 review